Abstract: Cardiovascular disease (CVD) remains the leading cause of death worldwide. To date, decades of research has established LDL-C (low-density lipoprotein cholesterol) as a causal factor in the development of atherosclerotic CVD. Statin therapy, supported by a broad evidence base, has demonstrated its superior efficacy in reducing LDL-C and subsequent cardiovascular risk. It therefore currently forms the mainstay of lipid-lowering therapy as recommended by international guidelines. Statin therapy is indicated in the secondary prevention of atherosclerotic CVD, as well as genetic causes of dyslipidemia (such as familial hypercholesterolemia). Although this strategy targets those most at risk, it merely addresses those most susceptible and does not account for the fact that most cardiovascular events occur in those at moderate to low risk. In addition, there is evidence for use in primary prevention such as in those with diabetes mellitus, chronic kidney disease, and high risk of future atherosclerotic CVD as determined by risk prediction calculators. Risk prediction tools, however, are far from perfect and do not accurately account for those at low short-term but high lifelong risk. Considering the loglinear relationship between LDL-C reductions and reductions in risk of atherosclerotic CVD, even in those at very low risk of future events, a clinical question posed is can we and should we shift the entire risk distribution by treating everyone? The present review discusses these issues in more detail outlining arguments for and against each approach. (Circ Res.
C ardiovascular disease (CVD) remains the leading cause of death worldwide 1 with a large economic burden on society despite significant advances in CVD prevention. Numerous risk factors have been identified, which initiate or accelerate the atherosclerotic process, and which similarly when controlled reduce future cardiovascular risk. 2 Of these risk factors, none has attracted more attention than cholesterol. We now know that cholesterol synthesis occurs in a series of reactions via the mevalonate pathway from acetyl-coenzyme a (acetyl-CoA). This process takes place predominantly in the liver, and conversion of acetyl-CoA to mevalonate occurs through the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-CoA reductase. In 1973, the Japanese scientist, Akira Endo, was able to isolate the first known inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, called at the time compactin. 3, 4 It was not, however, until the landmark 4S (Scandinavian Simvastatin Survival Study) conducted in the 1990s that there was unequivocal evidence that treatment with statins and lowering of cholesterol reduced the risk of future CVD. 5 This first trial created the impetus for further research, and subsequent trials confirmed the findings from 4S and extended the observations to other populations 5a-7 paving the way for statins to become the cornerstone of lipid-lowering therapies.
As we stand in 2018, we now have decades of research establishing that the accumulation of the cholesterol cargo carried by LDL (low-density lipoprotein) particles within the arterial wall is the initiating factor in atherogenesis and its clinical manifestation as coronary artery disease. Large-scale epidemiological studies, Mendelian randomization genetic studies, and trials of therapeutic interventions have additionally established that LDL-C (LDL cholesterol) is a causal factor in developing atherosclerotic CVD (ASCVD). [8] [9] [10] Since coming off-patent statins are relatively inexpensive (estimated cost of $2 per month), are overall well tolerated with few serious objectively documented adverse effects 11, 12 and have contributed to the declines in mortality from coronary heart disease. 13, 14 Their superior efficacy in reducing LDL-C and subsequent cardiovascular risk provides a broader evidence base for their use compared with other lipid modification therapies such as fibrates, nicotinic acid, bile acid sequestrants, and ezetimibe, which is why statin therapy currently forms the mainstay of lipid-lowering therapy.
When Are Statins Mandatory? Secondary Prevention of ASCVD
In all international guidelines, there is agreement that statin therapy for the secondary prevention of ASCVD is indicated as these patients are considered to be at high risk and the cardiovascular benefits of treatment are supported by a large evidence base. 10, [15] [16] [17] Although 4S demonstrated the benefits of simvastatin in patients with prior myocardial infarction (MI) and elevated cholesterol (mean LDL, 188 mg/dL) using a treat-to-target approach, the larger LIPID trial (Long-Term Intervention with Pravastatin in Ischaemic Disease) extended the findings to include patients with unstable angina 18 and the CARE trial (Cholesterol and Recurrent Events) extended observations to patients with coronary disease and lower levels of LDL cholesterol. 19 Both trials studied a second statin (pravastatin) suggesting a class effect. The Heart Protection Study 6 demonstrated that the proportional risk reduction was independent of baseline LDL-C suggesting that risk rather than LDL-C should be the determinant of treatment choice. All prior trials had excluded patients with a history of MI in the previous 4 to 6 months, and thus, the MIRACL trial (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) was the first study to demonstrate that high-dose statins (atorvastatin 80 mg) reduced clinical events versus placebo if started in hospital at the time of an acute coronary syndrome. 20 However, it was not known whether this approach was better than lower doses of statins and this was resolved by the landmark PROVE-IT TIMI 22 trial (Pravastatin or Atorvastatin Evaluation and Infection TherapyThrombolysis in Myocardial Infarction 22) which demonstrated that high doses were better than lower doses in patients with acute coronary syndrome. 21 Further supportive evidence and in multiple populations has come from the TNT (Treating to New Targets) and IDEAL trial (Incremental Decrease in End Points Through Aggressive Lipid Lowering) 22, 23 with atorvastatin and the REAL CAD trial (High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease) in Japanese patients with pitavastatin. 24 Although these trials used a fire-and-forget approach, there is evidence from the ALLIANCE trial (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events) of a treat to target approach for patients with coronary artery disease. 25 These data were synthesized in the CTT (Cholesterol Treatment Trialists) collaboration to provide unprecedented power and precision around safety and efficacy in subgroups and exploring hypotheses previously not possible. 26, 27 The major findings in a series of publications demonstrated that the relative risk reduction across populations is proportional to the absolute difference in LDL-C with about one-fifth to one-quarter reduction per 39 mg/dL reduction in LDL-C. This was true for comparisons versus placebo and for higher versus lower doses of statins. Importantly, the relative reduction in risk was constant per 39 mg/dL across disease and risk factor categories. A key finding is that the greatest absolute benefits occur in those with the highest baseline risk, reinforcing the need for greater absolute reductions in LDL-C among those at greatest risk. In light of this, and in the absence of randomized control trials using a treat-to-target approach, international guidelines now consider predicted cardiovascular risk levels alongside LDL-C levels when assessing cardiovascular risk profiles and initiating therapy. This is in addition to advocating lifestyle interventions (smoking cessation, weight loss, exercise, healthy diet, adequate glycemic, and blood pressure control). 10, 16, 17 
Familial Hypercholesterolemia
Familial hypercholesterolemia is an autosomal dominant condition characterized by elevated LDL-C levels and an increased risk of premature atherosclerotic coronary artery disease. Untreated heterozygous individuals have a 2-fold excess of coronary heart disease-related deaths relative to 29, 30 Before statin therapy was available, mortality from coronary disease was 100-fold in young patients (20-39 years) . 31 Treated individuals with heterozygous familial hypercholesterolemia have an overall mortality similar to that of the general population. 28 Given the natural history of this condition, all affected individuals are automatically considered high risk for future events, risk prediction calculators are not applicable, and statin therapy is indicated and should be initiated from childhood, irrespective of the presence of established CVD and ideally before its development. Unfortunately for homozygous carriers, current lipid-lowering therapies are insufficient to reduce future risk of ASCVD with patients requiring regular LDL apheresis.
Where Does the Debate Still Lie? Primary Prevention With High LDL-C
Many younger patients (in particular those with elevated LDL-C levels) have been estimated to benefit from longterm therapy even if they are at low short-term risk as they carry a high lifelong risk of CVD because of lifelong accumulation of cholesterol cargo. 32, 33 Although high LDL-C levels (LDL-C levels ≥190 mg/dL) can be associated with underlying genetic disorders of lipid metabolism such as in familial hypercholesterolemia, the majority of patients with a clinical diagnosis will not have a monogenic disorder with a known causal mutation. 29 Crucially though, a phenotypic diagnosis of familial hypercholesterolemia, defined as LDL-C levels ≥190 mg/dL, is itself associated with an up to 5-fold increased 30-year risk of coronary artery disease and accelerates coronary artery disease by 10 to 20 years in men and 20 to 30 years in women. 34 The first primary prevention trial was conducted in 1989. 6 Recent post hoc analysis of 5529 participants from the original WOSCOPS trial (West of Scotland Coronary Prevention Study) demonstrated that at 20-year follow-up individuals allocated to pravastatin with an LDL-C ≥190 mg/dL (n=2560) had a 28% (P=0.02) reduction in the risk of coronary heart disease death, 25% (P=0.009) reduction in the risk of cardiovascular death, and an 18% (P=0.02) reduction in all-cause mortality. 35 Placebo-treated patients with an LDL-C ≥190 mg/dL were also noted to have a 2-fold higher observed risk of major cardiovascular events than would have been predicted by a risk calculator (Pooled Cohort Equation used). The vast majority (about 67%) would have had a 10-year predicted risk of <7.5% and therefore would have been ineligible for statins.
Currently, despite this evidence, international guidelines do not have agreement on treating adult patients with isolated elevations of LDL-C (defined as ≥190 mg/dL) in the absence of a confirmed genetic diagnosis of dyslipidemia. Canadian 15 and American 16 guidelines recommend statin therapy regardless of predicted 10-year cardiovascular risk. European 10 guidelines recommend statin therapy if 10-year risk of future fatal events is >5%. Given the recent findings from WOSCOPS in a pure primary prevention population, these guidelines perhaps need to be revised.
Primary Prevention With Low Risk of CVD
Whereas those individuals with established ASCVD represent a very high-risk group whose gene-environment interaction is such that they already have disease, at a population level the majority of cases of coronary disease do not occur in this group. In fact, they occur in low-to moderate-risk individuals who do not yet have clinical manifestations of ASCVD. 36, 37 The AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study), JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin), and HOPE-3 trial (Heart Outcomes Preventions Evaluation 3) studied primary prevention cohorts at low risk of CVD 7, 38, 39 and demonstrated significant reductions in major coronary events in the intervention arms compared with placebo (Number Needed to Treat [NNT] for composite cardiovascular outcomes 45, 86, 91, respectively). 40 Although AFCAPS/TexCAPS had placebo event rates of 1.5% per year and JUPITER 0.85% per year, HOPE-3 had the lowest event rate of 0.7% per year extending the earlier observations of AFCAPS/TexCAPS and JUPITER in a low-risk population.
In the CTT analysis of statin therapy in patients at low risk of vascular disease, for patients in the 2 lowest categories of risk (<5% and ≥5% to <10%), the proportional reductions in major vascular events per 39 mg/dL LDL-C reduction were at least as large as those in the higher risk categories even after stratification by age, sex, or baseline LDL-C. 9 Even after excluding patients with diabetes mellitus (DM) or chronic kidney disease (CKD) from the lower risk categories, this had little effect on the proportional reductions in major vascular events. The study predicted NNT of 167 and 67 to prevent major vascular events in the lowest 2 baseline risk categories (<5% 5-year risk and ≥5% to <10% 5-year risk, respectively). These numbers are within the range considered appropriate in primary prevention, for example, for the treatment of hypertension and importantly the proportional reductions in lower risk groups appear to be larger than those in higher risk groups. This seems to be in keeping with data demonstrating that exposure to lower LDL-C levels from a young age may produce larger risk reductions given the overall reduced lifetime cumulative exposure to LDL-C. 41 Further analysis from the Cochrane group also reported similar benefits of statins at low levels of CVD risk, 42 and therefore in light of this together with the CTT evidence, 9 their previous caution in using statins for people at low risk of cardiovascular events was no longer tenable and effectively withdrawn.
In a meta-analysis of Mendelian randomization studies of genetic polymorphisms resulting in lower LDL-C levels from birth, 41 prolonged exposure (average over 50 years) to lower LDL-C was associated with a 3-fold greater reduction in the risk of coronary heart disease compared with statin therapy (average exposure 5 years), per unit lower LDL-C. This finding has profound implications on the future of cardiovascular prevention and further supports the population theory by Rose 43 but also that small reductions maintained for a longer period of time provide similar effect to large reductions over a short time scale. Ference et al 41 also demonstrated that the effects of long-term exposure to lower LDL-C on the risk of coronary heart disease are independent of the mechanism by which the LDL-C is lowered and for how long. As such, diet and exercise may be as effective in lowering cumulative LDL-C exposure if started early, although this may be harder to maintain lifelong.
Chronic Kidney Disease
Another area of debate is in patients with CKD, defined as an estimated glomerular filtration rate (eGFR) <60 mL min −1 1.73 m −2 or those with preserved eGFR but with an increased urinary albumin:creatinine ratio ≥3 mg/mmol for at least 3-month duration. CKD is associated with an increased risk of CVD 44 and has been additionally associated with a worse prognosis after MI. 45 In spite of this, primary prevention clinical trials have often excluded patients with severe CKD when recruiting. 46 The cardiac pathophysiology of worsening CKD becomes progressively more complex, and as CKD progresses to end-stage renal failure, the potential for treatment to have a significant impact on mortality and morbidity can be reduced as other nonatherosclerotic events may be the predominant cause of death for which statin therapy is less effective (heart failure [HF], arrhythmia, hemorrhagic stroke).
In the SHARP trial (Study Heart and Renal Protection), 47 9270 patients with a serum creatinine level >150 μmol/L for men and >130 μmol/L for women were randomized to either combination therapy of simvastatin and ezetimibe or placebo.
In the intervention arm, there was a 17% (P=0.0021) proportional reduction in the primary end point of MI, coronary death, ischemic stroke, or revascularization. Within this study, 37% of patients in the intervention arm had an estimated eGFR of ≥30 to <60 mL min −1 1.73 m −2 and 41% ≥15 to <30 mL min −1 1.73 m −2 . Of note, there was no statistically significant benefit seen in the primary end point in patients already receiving hemodialysis, a finding previously observed in the 4D trial (Die Deutsche Diabetes Dialyse) 48 and AURORA trial (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events). 49 In a meta-analysis by the Cholesterol Treatment Trialists' Collaboration, 50 statin therapy reduced the risk of major vascular event by 21% (P<0.0001) per 39 mg/dL reduction in LDL-C. As eGFR declined, there was a significant trend toward smaller proportional effects on major vascular events (P=0.008 for trend). This trend was postulated to be as a result of a reduced proportion of cardiac deaths attributed to coronary heart disease as eGFR declined; coronary heart disease was attributed to 57% of cardiac deaths in patients with an eGFR >60 mL min . The meta-analysis further concluded that there was little evidence that statin-based therapy was effective in patients starting treatment after dialysis had been initiated.
Currently, there is recognition across international guidelines of insufficient evidence to recommend initiating statin therapy in patients receiving hemodialysis. With CKD, the recommendations are less consistent. The Kidney Disease: Improving Global Outcomes group guidelines on lipid management in CKD 51 recommend statin therapy in adults ≥50 years old. For those <50 years, treatment is recommended if ≥1 other risk factors are present. United Kingdom 17 and Canadian 15 guidelines recognize that patients with CKD are high risk, and therefore, statin therapy is advised regardless of LDL-C level, however, unlike UK guidance, for those <50 years age, Canadian guidelines suggest consideration of individual risk factors before initiation of statin therapy. European 10 guidance advocates statin therapy for patients with CKD based on their LDL-C levels, and the American Heart Association/American College of Cardiology guidance makes no clear recommendation on CKD nor is it included as part of their risk prediction calculator.
Diabetes Mellitus
DM, including both type 1 DM and type 2 DM (T2DM), is considered an independent risk factor for the development of CVD, [52] [53] [54] and patients with DM experience worse outcomes after acute MI than those without DM. 55 DM doubles the risk of CVD 56 and results in about half a decade of life lost. 57 There are few randomized control trial data investigating statin therapy specifically in patients with DM despite a number of key trials included a small subset of patients with DM.
The CARDS (Collaborative Atorvastatin Diabetes Study) 58 was the first study to definitely prove that lipid lowering was beneficial as primary prevention in patients with DM. In this study, 2838 patients with T2DM, no previous CVD, and LDL-C <160 mg/dL were randomized to either atorvastatin 10 mg daily or placebo. The trial was terminated early and demonstrated a 37% (P=0.001) reduction in the incidence of major cardiovascular events irrespective of age and sex in those receiving atorvastatin. In a post hoc analysis of 743 patients with baseline LDL-C <100 mg/dL, there was a 26% reduction in major cardiovascular events. 58 In 2008, a meta-analysis of individual patient data from 14 trials which included patients with DM was conducted by the CTT Collaboration to provide further information on the uncertainties which existed. 59 Among patients with DM, there was a 21% (P<0.0001) proportional reduction in major vascular events per 39 mg/dL LDL-C reduction. This was similar to the reduction seen in patients without DM suggesting that the beneficial effects of statin therapy were not attenuated by the presence of DM. Further subgroup analysis demonstrated that this proportional reduction persisted irrespective of the presence or not of prior vascular disease or pretreatment LDL-C level. Although most trial participants had T2DM, there was no evidence that the effects of statin treatment in type 1 DM (as defined within trials rather than contemporary criteria) differed from that in T2DM. There was also a significant 9% reduction in all-cause mortality per 39 mg/dL LDL-C reduction, as well as a significant reduction in mortality because of coronary heart disease. Even when including the ASPEN (Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in NonInsulin Dependent Diabetes Mellitus) 59a and the 4D, 48 neither of which showed a statistically significant reduction in their primary outcomes, the CTT results did not differ significantly.
Despite the trial data demonstrating improvements in cardiovascular mortality irrespective of the type of DM, sex, or LDL-C level, to date, international guidelines while recognizing the importance of DM as a risk factor for future CVD are not as clear-cut. In the United Kingdom, patients with T2DM still need to meet the 10% 10-year CVD risk (QRISK2) threshold, and patients with type 1 DM must meet an age criterion or have microvascular diabetic complications or other cardiovascular risk factors before prescribing statins. 17 Canadian guidance is similar. 15 American guidance advocates high-intensity February 1, 2019 statin therapy to patients with DM who are >40 years of age, and their risk prediction score reaches threshold (≥7.5%) and moderate intensity for other patients with DM. 16 European guidance is perhaps more in keeping with the current evidence base recommending statin therapy in all patients with type 1 DM or T2DM above the age of 40 years regardless of LDL-C level or predicted risk score, recognizing the high lifetime risk of DM on CVD outcomes. 10 Statin trials in patients with DM did not recruit those under the age of 40 years old. As such, current guidance suggests that treatment for patients with DM under the age of 40 years should be physician guided and that further evidence is required.
As the lifetime risk of ASCVD among those with DM is so high and the younger the age at which DM is diagnosed the greater the life years lost, while not specifically mandated, there is a reasonable argument to be made for a discussion to be had with younger patients about the benefits of early treatment, that is, irrespective of age.
Elderly >75 Years
Given our aging population, CVD prevention becomes increasingly relevant. Statin therapy in the elderly is effective at reducing LDL-C and well tolerated. 60 Unfortunately, few specific primary prevention trials in the elderly exist.
A 2013 meta-analysis was conducted of primary prevention trials which included elderly patients. Elderly was defined as aged ≥65 years, although the mean age was 73.0±2.9 years, 42.7% females, 24 674 patients in total. Of note, the analysis was based on aggregate and not individual patient data. This demonstrated a significant proportional reduction in the risk of MI (39.4%, P=0.003) in statin-treated patients compared with placebo. 61 The incidence of stroke was reduced by 23.8% (P=0.006). There was, however, no significant difference in the risk of all-cause death compared with placebo. This may be partially explained by other competing comorbidities because of advanced age.
In a recent meta-analysis of the JUPITER and HOPE-3 trials, 62 a 26% relative risk reduction was observed for those >70 years old for the end point of nonfatal MI, nonfatal stroke, or cardiovascular death (P=0.0048). The authors suggest that considering the higher event rates in those ≥70 years old along with comparable relative rate reductions, this would imply greater absolute rate reductions and, therefore, fewer NNT in the elderly population. However, there is recognition that the number of patients ≥80 years of age in trials is modest, and any suggestions would be extrapolations of existing results rather than objective evidence of positive outcomes in those ≥80 years of age. Presently, the clinical trial of STAREE (Statin Therapy for Reducing Events in the Elderly; URL: http:// www.clinicaltrials.gov. Unique identifier: NCT02099123) examines whether treatment with atorvastatin 40 mg compared with placebo will prolong overall survival or disability-free survival among healthy elderly people (≥70 years old).
International guidelines for statin use in the elderly are synoptic. As the European Atherosclerosis Society/European Society of Cardiology guidance mentions, there is no evidence for the decreasing effectiveness of statins in patients >75 years of age. Aside from the UK-based QRISK2 calculator which is recommended for use in patients <84 years of age, other major risk prediction tools are recommended for use in patients <75 years. The Pooled Cohort Equation can provide information on predicted 10-year risk to those 76 to 79 years of age but more as an added tool to help inform treatment decision.
In general, the advice is that physicians should take into consideration individual patient circumstances when prescribing statins for the elderly, and treatment should be reviewed regularly. Whereas treating elderly patients with a lifespan of 5 years at high risk of CVD may appear intuitive, treating those at lower risk with a shorter lifespan perhaps makes little sense. Finally, calculating risk using conventional methods of shortterm risk is inappropriate as they are heavily age dependent and will tend to over-score older patients even in the absence of other risk factors. An alternative might be to look at event-free life years gained. So, for instance, subjecting a patient of 80 years of age to 2 years of treatment for a gain of 2 months may better inform a discussion than a 10-year risk of 40%.
Heart Failure
On the background of small studies 63, 64 suggesting that statin therapy may be of benefit in patients with HF, 2 randomized control trials were set up investigating statin therapy specifically in an HF population. The GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza cardiaca) established the GISSI-HF trial 65 investigating rosuvastatin 10 mg daily or placebo in chronic HF New York Heart Association classes II to IV irrespective of etiology or type of HF. This study did not show any benefit in the intervention arm, although compliance with statin therapy was a major confounder.
The CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) 66 randomized 5011 patients with New York Heart Association class II-IV ischemic, systolic HF to rosuvastatin 10 mg daily or placebo. This trial additionally demonstrated no significant difference in coronary outcome or death from cardiovascular causes between the 2 groups, although the study population was elderly patients with ischemic etiology where the disease may have been too advanced to modify. Of note, there were significantly fewer hospitalizations in the intervention arm than in the placebo arm.
In a meta-analysis of unpublished data from both primary and secondary prevention statin trials which included patients with HF, statin therapy resulted in an approximate 10% reduction in first nonfatal HF hospitalizations but not HF death. 67 The relative risk reduction for nonfatal HF hospitalizations was similar between primary and secondary prevention trial participants, although the absolute risk reduction was greater in secondary prevention trials where HF event rates were higher. Of note, only 10% to 15% of nonfatal HF hospitalizations were preceded by a documented within-trial nonfatal MI. The mechanism by which statins reduce nonfatal HF hospitalizations is not obvious; however, the absence of a significant effect on HF death may be attributed to nonischemic etiology as the cause of death in HF patients (pump failure, arrhythmias).
Considering current published data, there is no evidence to discontinue statin therapy in HF patients already on treatment for other indications. In the context of primary prevention, however, there does not appear to be enough evidence at present to support its use. This is currently reflected in international guidance.
Why Not for All?
The relation between blood cholesterol and cardiovascular risk is continuous 68 as such there is no definite threshold to initiate treatment so where do we draw the line? We know that the proportional reduction in vascular events continues even in individuals at low risk of vascular disease, and there is a linear association between achieved LDL-C level and cardiovascular outcomes. 69 Individuals with a higher absolute risk are likely to gain the most from any risk reduction; however, the majority of vascular events occur in those at lower risk as they are much larger in numbers. The proportional risk reductions are consistently around 21% per 39 mg/dL reduction in LDL-C level. An estimate of the benefits of statin treatment suggests that lowering LDL-C by 78 mg/dL with atorvastatin (a treatment considered effective and low cost at about $2 per month) for 5 years in 10 000 patients would prevent major vascular events in about 1000 secondary prevention patients (10% absolute benefit) and 500 primary prevention patients (5% absolute benefit). 70 In the CTT meta-analysis, 9 the observed annual rate for major vascular events was 0.6% and 1.6% in the 2 lowest risk categories (<5% and ≥5% to <10%, respectively).
If one's absolute risk short term was so low, would one want to take a tablet for life in the hope of gains much later and when does treatment not become worthwhile? For antihypertensive treatment which carries the same risk continuum, this is usually where adverse effects of treatment outweigh any benefits. Although there is no evidence of increased risk of death from nonvascular causes or cancer or cognitive impairment in primary prevention, 9, 27, 42, 70, 71 other adverse effects are worth mentioning when considering the net benefit of statins.
Statin therapy is associated with a small increased risk of myopathy when defined as muscle pain with increased serum creatine kinase levels >10× the upper limit of normal and less commonly that of rhabdomyolysis (a severe form of myopathy with muscle breakdown and myoglobin release). The absolute excess incidence of myopathy as per the above definition is estimated at 1 case per 10 000 people treated per year with standard statin dose and even less for rhabdomyolysis which is estimated at between 2 and 3 cases per 100 000 people treated per year. 27, 70, 72 The risk of myopathy is dose related 73 with symptoms and biochemical parameters usually resolving once statin therapy is stopped.
Statin-associated muscle symptoms are often reported and represent a big hurdle to recommending more widespread use of statins. Myalgia (muscle pain without significant changes in serum creatine kinase levels) with statin therapy is reported with a frequency of between 9% and 20% in the outpatient setting. 74 With conflicting rates of muscle-related symptoms between observational studies and randomized controlled trials, a debated issue is to what extent symptoms of myalgia without CK elevations are real or because of a nocebo effect. 12 In the ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm) although there was no excess of reports of muscle-related adverse events among patients assigned to statin therapy during the blinded phase, there was a significant excess when patients knew that they were taking a statin in the nonblinded phase, in keeping with a possible nocebo effect. 75 In contrast, in the GAUSS 3 trial crossover phase ≈42.6% of the cohort of 491 patients (previously intolerant to ≥2 statins) reported muscle-related symptoms on blinded rechallenge with statins but not on placebo. 76 This supports the notion that symptoms are reproducible during blinded statin challenge but also that some patients can tolerate a statin with rechallenge. Of note, 199 or the 491 entered the blinded part B where they were randomized to ezetimibe or a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor. During that phase, 28.8% reported muscle symptoms on blinded ezetimibe, whereas 20.7% reported them on a PCSK9 inhibitor. In the Odyssey Alternative trial, patients previously intolerant to ≥2 statins were randomized in a blinded fashion to a PCSK9 inhibitor, ezetimibe, or statin. 77 Any skeletal muscle-related adverse event was reported in 32.5%, 41.1%, and 46%, respectively, although differences in myalgia were less marked at 24.6%, 23.4%, and 27%, respectively. Of interest, muscular weakness was more common with statin rechallenge at 0.8%, 1.6%, and 6.3%, respectively. These data demonstrate that in many people statin-associated muscle symptoms are reliably reproduced or limit the ability to continue treatment.
Regardless of whether myalgia symptoms are nocebo or true, patient perceptions on tolerability determine compliance and can frequently result in discontinuation of statin therapy. We must therefore seek ways of improving adherence to treatment and in doing so, although we may not at present be able to identify these individuals in the absence of a rise in creatinine kinase, informing our patients that they may have something real, which may then allow us to trial different approaches to ensure they remain on statin therapy. For example, switching to an alternative statin has been showed to improve tolerability. 78, 79 An increased incidence of hemorrhagic stroke has been suggested with an estimated annual excess risk of 0.5 per 1000 people treated over 5 years per 39 mg/dL LDL-C reduction. 9 In the SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels), 80 a 20% significant proportional reduction in major vascular events was seen which included a significant reduction in ischemic stroke despite a significant excess of hemorrhagic stroke. A criticism of the SPARCL results, however, is that this study evaluated atorvastatin in patients with a prior history of stroke or transient ischemic attack. A meta-analysis of 248 391 patients based on data from randomized control trials, cohort studies, and case-control studies, however, found no significant increased risk of intracerebral hemorrhage. 81 At present, no change in statin treatment is indicated in patients with a history of cerebrovascular disease. 12 Third, statin therapy has been showed to lead to a proportional increase in the incidence of T2DM in the order of 9%. 82 In the JUPITER trial, 7 rosuvastatin 20 mg daily was associated with a 39% proportional reduction in the primary end point (P=0.0001) and a 28% increase in DM (P=0.01) in individuals with ≥1 risk factors. For participants with no DM risk factors, there was no statistically significant effect of statin therapy on the incidence of new-onset DM. For every 54 new cases of DM diagnosed, a total of 134 vascular events or deaths were avoided.
These findings are consistent in a further meta-analysis. 82 The risk of development of DM was highest in trials with older participants, and treatment of 255 patients for 4 years resulted February 1, 2019 in 1 extra case of DM. Baseline fasting glucose levels and features of metabolic syndrome seem predictive of new-onset T2DM suggesting that these individuals may already be at higher risk of DM as a result of their comorbidities. 83 Of note, cardiovascular and mortality benefits of statin therapy exceeded any DM risk including those at high risk of developing DM, and the adverse effect of new-onset T2DM is estimated to be >50× smaller than the absolute benefit observed with statin therapy. 9 In addition, observational data show that patients who developed DM while on statin therapy had lower rates of macro-and microvascular disease complications 84 but also the conversion rate to DM in patients with confirmed impaired glucose tolerance but not on a statin is higher than those on statin. 12, 85 Overall, despite the small excess in hemorrhagic stroke or new-onset T2DM, this does not impact significantly on the longterm cardiovascular benefits and absolute reductions in major vascular events over time while on statin therapy as untreated risk is cumulative. Although, one could argue that in patients at low risk you would expect that treatment to prevent disease should not cause any harm in order to be generally acceptable.
Accepting that the benefits of statin treatment in high-risk individuals (established CVD, CKD, DM >40 years of age, patients reaching treatment threshold based on risk factors, high LDL) outweigh any risk, we are left with individuals at lower risk. The danger with labeling these patients as low risk is that we assume risk prediction calculators are accurate. Currently, risk prediction calculators incorporate recognized causal associations between risk factors and CVD in an attempt to identify those most at risk and hence most likely to benefit from lipid-lowering therapies. 10, 16, 86, 87 Risk prediction underlies national primary prevention guidelines as this directs appropriate use of statin therapy.
Although our risk prediction abilities have improved, problems with calibration and discrimination remain, in part reflecting the complex multifactorial nature of CVD. [88] [89] [90] A criticism of present risk prediction tools is that they do not accurately represent lifetime risk, instead focusing on 10-year risk as well as many being derived from old patient cohorts rather than more contemporary patient data. Risk prediction tools are age and gender dependent such that young patients (<40 years) and women are unlikely to score high enough for treatment in the absence of specific risk factors. The concept of lifetime risk exposure has begun to be increasingly recognized within international guidelines. 10, 15, 16 Given the lack of sufficient data for robust lifetime risk estimations and net benefit (efficacy and safety) of lifelong preventative treatment, guidelines in general do not as of yet recommend treatment decisions to be made solely based on lifetime risk. It is perhaps this lack of long-term safety data for statin therapy in those at low risk that remains the major barrier to more widespread use of statin therapy. Nonetheless, if lifetime risk is perceived to be elevated, then this serves as an opportunity to emphasize lifestyle changes and engage in a discussion about the potential benefits/ risks of statins in young individuals on a case-by-case basis.
The next dilemma about providing statin treatment for all is the cost-effectiveness of treatment. In fact, generic statin treatment is cost-effective in individuals at annual vascular disease risk down to at least 1% but is dependent on patient preference for taking daily medication. [91] [92] [93] [94] Time-to-first-event analysis is important and constitutes the main reporting measure when measuring treatment effect in statin trials. These results are subsequently used to generate NNT as well as cost-effectiveness analysis. Individual patients, however, do not suffer just 1 event but may have subsequent events. With evidence that statin therapy reduces the risk of subsequent events, [95] [96] [97] the total burden of primary end points, and therefore, ASCVD events may be underestimated. If the true total clinical ASCVD events were to be incorporated into statistical analyses rather than time-to-first event alone, this would likely result in smaller NNT and improved cost-benefit assessments.
Conclusions
The use of statin therapy in higher risk individuals such as those with ASCVD, DM >40 years, genetic dyslipidemias, and high-risk primary prevention is universally accepted to provide benefit, and there are clearly patient cohorts where statin therapy has either not been proven to be effective (HF, hemodialysis patients) or not studied (end of life, malignancy). The evidence demonstrates that primary prevention is effective at reducing cardiovascular risk and treating those at low risk is also cost-effective provided patients take their medication.
A challenge of widespread statin use will be compliance with daily medication especially in those who will not see a short-term benefit as well as addressing muscle-related adverse events. More importantly given the lack of long-term safety data for statin therapy over multiple decades of therapy in low-risk populations, more widespread use of therapy outside of what is recommended by international guidance cannot yet be justified.
In his seminal article, Rose 43 discussed the Prevention Paradox. This is a prevention measure which brings benefit to the population but offers less to the participating individual. This population strategy, however, can have a profound effect, and numerous examples exist, including childhood immunizations, legislation mandating the use of seat belts, banning smoking in public places. Statin treatment in low-risk individuals may bring little short-term benefit to each individual; indeed, some of them may never have experienced an atherosclerotic cardiovascular event; however, it brings with it a large benefit to the population as a whole. If we take into account potential lifetime benefits and the potential for life years gained, then individual gains may be more marked if long-term safety data allow for widespread statin use.
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